伊立替康药物洗脱微球治疗贝伐珠单抗化疗无应答的结直肠癌同期肝转移
结果显示DEBIRI客观缓解率达54.5%,但未延长生存;DEBIRI前CT对比增强率(CER)可预测客观缓解(AUC=0.737)。
要点
- DEBIRI对贝伐珠单抗化疗无应答的结直肠癌肝转移有可接受的局部控制率。
- DEBIRI前CT的对比增强率(CER)可预测DEBIRI客观缓解。
- 该局部控制未转化为生存获益。
核心结论
- DEBIRI对贝伐珠单抗化疗无应答的结直肠癌肝转移可实现可接受的客观缓解,但未延长生存。
- DEBIRI前CT对比增强率(CER)可预测客观缓解(AUC=0.737,p<0.01)。
研究设计与样本
- 无应答组进一步分为未接受DEBIRI组(n=23)和接受DEBIRI组(n=19)。
- 治疗反应分别用形态学标准和Choi标准评估,记录无进展生存期和总生存期。
- 分析DEBIRI前CT参数与DEBIRI治疗反应的相关性。
诊断标准与关键数值
- 贝伐珠单抗化疗应答组、无应答组和無应答+DEBIRI组的中位无进展生存期分别为11、12和4个月(p<0.01)。
- 三组中位总生存期分别为36、23和12个月(p=0.01)。
- 无应答+DEBIRI组33个转移灶中18个(54.5%)达到客观缓解。
- DEBIRI前对比增强率(CER)预测客观缓解的AUC=0.737(p<0.01)。
临床应用与阅片要点
- 对于贝伐珠单抗化疗无应答的结直肠癌肝转移患者,DEBIRI可作为可接受的局部治疗选择。
- DEBIRI前CT测量的对比增强率(CER)可用于预测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy of drug-eluting beads loaded with irinotecan (DEBIRI) in colorectal cancer (CRC) patients with synchronous liver-only metastases non-responsive to bevacizumab-based chemotherapy (BBC).
METHODS: Fifty-eight patients were enrolled in this study. Treatment response to BBC and DEBIRI were determined by the morphological criteria and Choi's criteria, respectively. Progression-free survival (PFS) and overall survival (OS) were recorded. The correlation between pre-DEBIRI CT parameters and treatment response to DEBIRI was analyzed.
RESULTS: CRC patients were divided into the BBC responsive group (R group) (n = 16) and the non-responsive group (n = 42), which was further divided into the NR group (23 patients who did not receive DEBIRI) and the NR+DEBIRI group (19 patients who received DEBIRI after failing BBC). Among the R, NR and NR+DEBIRI groups, the median PFS were 11, 12, and 4 months, respectively (p < 0.01); median OS were 36, 23, and 12 months, respectively (p = 0.01). In the NR+DEBIRI group, 33 metastatic lesions were treated with DEBIRI, of which 18 (54.5%) reached objective response. The receiver operating characteristic curve showed that the contrast enhancement ratio (CER) before DEBIRI could predict objective response (AUC = 0.737, p < 0.01).
CONCLUSION: In CRC patients, DEBIRI can achieve acceptable objective response for liver metastases non-responsive to BBC. However, this locoregional control does not prolong survival. The pre-DEBIRI CER can predict OR in these patients.
ADVANCES IN KNOWLEDGE: DEBIRI can act as an acceptable locoregional management in CRC patients with liver metastases non-responsive to BBC, and the pre-DEBIRI CER is a potential indicator of locoregional control.
引用
- Hsu, Chang, Chang, et al. Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy. Br J Radiol. 2023. PMID: 36802795. doi:10.1259/bjr.20220767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。